Volume 82, Issue 11 (February 2025)
Tehran Univ Med J 2025, 82(11): 824-833 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Bidari Zerehpoosh F, Saffari M, Sabeti S, Ebrahimzadeh K, Taheri M. Investigation of immunohistochemical markers in pathological samples of patients with pituitary neuroendocrine tumors. Tehran Univ Med J 2025; 82 (11) :824-833
URL: http://tumj.tums.ac.ir/article-1-13404-en.html
URL: http://tumj.tums.ac.ir/article-1-13404-en.html
Farahnaz Bidari Zerehpoosh1 
, Mahdieh Saffari1 , Shahram Sabeti *1 , Kaveh Ebrahimzadeh2 , Mahbobeh Taheri3
, Mahdieh Saffari1 , Shahram Sabeti *1 , Kaveh Ebrahimzadeh2 , Mahbobeh Taheri3
1- Department of Pathology, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
2- Skull Base Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
3- Skull Base Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.|Department of Community Medicine, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
2- Skull Base Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
3- Skull Base Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.|Department of Community Medicine, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Abstract: (1084 Views)
Background: This study aimed to investigate the markers ACTH, KI67, CAM5.2, GH, PRL, FSH, LH, TSH in pathological samples of patients with pituitary neuroendocrine tumors by IHC staining.
Methods: In this retrospective study, all patients with PitNETs who had undergone surgery at Loghman Hospital from 2020 to 2022 were included in the study. The slides were prepared by IHC staining and with the markers ACTH, KI67, CAM5.2, GH, PRL, FSH, LH, TSH were evaluated. IHC staining for SF1-PIT1-TPit transcription factors was performed for 16 patients with negative initial markers.
Results: 424 patients participated in this study. The mean and standard deviation of the age of the patients studied were 43.7 and 13.7 years, respectively. LH and FSH markers had the highest and TSH marker had the lowest proportion of positive cases. The possibility of LH and FSH markers being positive in men was significantly higher than in women, and conversely, the possibility of GH and ACTH markers being positive in women was significantly higher than in men. The possibility of LH and FSH markers being positive in patients over 40 years of age was significantly higher than in patients 40 years of age and younger, and conversely, the possibility of GH and PRL markers being positive in patients 40 years of age and younger was significantly higher than in patients over 40 years of age. Most cases (66.3%) were treated during the follow-up period.
Conclusion: The findings indicate that accurate pathological identification of tumors plays an important role in the selection of treatment methods, especially drug and surgical treatment, and can lead to improved patient management.
Methods: In this retrospective study, all patients with PitNETs who had undergone surgery at Loghman Hospital from 2020 to 2022 were included in the study. The slides were prepared by IHC staining and with the markers ACTH, KI67, CAM5.2, GH, PRL, FSH, LH, TSH were evaluated. IHC staining for SF1-PIT1-TPit transcription factors was performed for 16 patients with negative initial markers.
Results: 424 patients participated in this study. The mean and standard deviation of the age of the patients studied were 43.7 and 13.7 years, respectively. LH and FSH markers had the highest and TSH marker had the lowest proportion of positive cases. The possibility of LH and FSH markers being positive in men was significantly higher than in women, and conversely, the possibility of GH and ACTH markers being positive in women was significantly higher than in men. The possibility of LH and FSH markers being positive in patients over 40 years of age was significantly higher than in patients 40 years of age and younger, and conversely, the possibility of GH and PRL markers being positive in patients 40 years of age and younger was significantly higher than in patients over 40 years of age. Most cases (66.3%) were treated during the follow-up period.
Conclusion: The findings indicate that accurate pathological identification of tumors plays an important role in the selection of treatment methods, especially drug and surgical treatment, and can lead to improved patient management.
Type of Study: Original Article |
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
